Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy

P. Villani, P. Viale, L. Signorini, B. Cadeo, F. Marchetti, A. Villani, C. Fiocchi, M. B. Regazzi, G. Carosi

Research output: Contribution to journalArticlepeer-review

Abstract

The purpose of this study was to evaluate the pharmacokenetics (PK) profile of oral levofloxacin in human immunodeficiency virus-positive patients in steady-state treatment with nelfinavir (NFV) or with efavirenz (EFV) and to determine the effects of levofloxacin on the PK parameters of these two antiretroviral agents. For levofloxacin, plasma samples were obtained at steady state during a 24-h dosing interval. Plasma NFV and EFV concentrations were evaluated before and after 4 days of levofloxacin treatment. Levofloxacin PK do not seem affected by NFV and EFV. There was no significant difference between NFV and EFV plasma levels obtained with and without levofloxacin.

Original languageEnglish
Pages (from-to)2160-2162
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume45
Issue number7
DOIs
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy'. Together they form a unique fingerprint.

Cite this